Superluminal Medicines, Inc.
Superluminal Medicines is seeking a Research Associate to join its Biology team, focusing on cell biology, assay development, and screening to support early-stage drug discovery programs. The role involves performing routine mammalian cell culture, executing cell-based assays, and assisting in the development and optimization of new screening assays. The successful candidate will generate and analyze experimental data while ensuring compliance with laboratory practices and company policies.
Superluminal Medicines is a biotechnology company accelerating drug discovery and development to deliver next‑generation small‑molecule therapeutics. Their Hyperloop™ platform combines structure‑based drug design with AI‑driven computational methods and experimental validation to identify and optimize candidates. Initially focused on GPCR targets, their pipeline emphasizes patient‑centric precision to develop treatments for cardiometabolic diseases.
Axcelead DDP and Superluminal Announce the Intent to Collaborate on Drug Discovery Targeting Specific Molecular Mechanisms, continuing a productive relationship
Jun 23, 2025
Superluminal joins a $1.3B deal with series A backer Lilly
Aug 14, 2025
Lilly Obesity Deal Gives Superluminal More Shots On GPCR Goals
Aug 28, 2025
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Superluminal Medicines, Inc..
Superluminal Medicines, Inc. didn’t post a salary, so this is our estimate from similar listings.
Superluminal Medicines Closes $120 Million Series A Round
Sep 9, 2024